Episode Details
Back to Episodes
Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/could-rhopressa-protect-the-optic-nerve-not-just-lower-eye-pressure-a-new-trial-will-count-individual-glaucoma-nerve-cells
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells A newly registered study is asking an unusually direct question: does netarsudil (Rhopressa) preserve retinal nerve cells better than timolol when used by people with open-angle glaucoma? Rather than relying only on standard scans that measure the thickness of broad retinal layers, the researchers plan to use adaptive optics optical coherence tomography to image and count cells in the living eye. It is an exciting idea, but this is a small, early clinical test—not proof that Rhopressa protects the optic nerve independently of pressure. The trial’s design, its short treatment periods, and unresolved questions about the new imaging method all matter. So does a fundamental challenge: two medicines can produce similar pressure readings in the clinic while having different effects on pressure overnight, blood flow, or pressure variability. The new trial: what is registered The Phase 4 study, NCT07847073, is titled “Adaptive Optics OCT Evaluation of Rhopressa’s Effects on the Retinal Ganglion Cells in Glaucoma Patients.” It was first posted on September 29, 2026, after submission on September 22. The registry lists it as recruiting, with an estimated start date of October 1, 2026. That estimated date is not confirmation that the first participant was enrolled on that day. The planned study completion date is January 1, 2028. ClinicalTrials.gov study record () For the full table, please open this article on visualfieldtest.com. The two treatment regimens are: Netarsudil 0.02%: one drop in the study eye once daily in the evening for six months. Timolol maleate 0.25%: one drop in the study eye twice daily, morning and evening, for six months. One group receives netarsudil first and then timolol; the other receives timolol first and then netarsudil. Trial interventions and outcomes () Who can take part—and what the registry does not say Participants must be at least 18 years old and have open-angle glaucoma with structural damage to the optic nerve or retinal nerve fiber layer, plus matching visual-field defects. Corrected visual acuity must be 20/50 or better, and participants must be able to fixate for imaging. The allowed refractive range is a spherical equivalent from +3 to −6 diopters, with cylinder under 3 diopters. People who are new to pressure-lowering drops, or who have completed a medication washout, must have an intraocular pressure between 18 and 34 millimeters of mercury. The record excludes people with certain other retinal diseases or optic-nerve conditions, or who cannot safely undergo washout. It does not state a formal glaucoma severity category, such as mild, moderate, or advanced. Nor does it publish the washout duration or specify different washout periods for different medicines. The record describes a switch at month six but does not specify a separate washout between treatment periods. Eligibility criteria and study arms () That missing information matters. A medication-free pressure reading after washout establishes eligibility, but it does not prove that participants will have the same pressure exposure on both study medicines. And an immediate switch at month six, if that